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Microbial pathogens have evolved many inge-
nious ways to evade host innate immune re-
sponses and phagocytic clearance (Flannagan 
et al., 2009; Diacovich and Gorvel, 2010; Neish 
and Naumann, 2011). Because all microbial and 
host cell surfaces are decorated with carbohy-
drate structures, glycan–receptor interactions 
play crucial roles in microbial pattern recogni-
tion as well as in the regulatory signals that gov-
ern normal immune cell activities (Comstock 
and Kasper, 2006). Consequently, a key viru-
lence strategy of many leading pathogens is to 
display sugars in a fashion that mimics or inter-
feres with host glycan–based immune functions 
(Nizet and Esko, 2009).
Sialic acids are 9-carbon-backbone sugars 
found in abundance on terminal glycan structures 
of mammalian cell surfaces, including all human 
cells. Human leukocytes express various mem-
bers of a rapidly evolving receptor family known 
as CD33-related sialic acid–binding immuno-
globulin-like lectins (Siglecs); sialylated glycans 
bind to Siglecs and modulate their function. 
Because many CD33-related Siglecs have an im-
munoreceptor tyrosine-based inhibitory motif 
(ITIM) and/or ITIM-like motifs in their intra-
cellular domain, engagement of sialic acid–
containing glycans can mediate an inhibitory 
signal (Crocker et al., 2007). Consequently, 
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Group B Streptococcus (GBS) causes invasive infections in human newborns. We recently 
showed that the GBS -protein attenuates innate immune responses by binding to sialic 
acid–binding immunoglobulin-like lectin 5 (Siglec-5), an inhibitory receptor on phagocytes. 
Interestingly, neutrophils and monocytes also express Siglec-14, which has a ligand-binding 
domain almost identical to Siglec-5 but signals via an activating motif, raising the possibility 
that these are paired Siglec receptors that balance immune responses to pathogens. Here we 
show that -protein–expressing GBS binds to both Siglec-5 and Siglec-14 on neutrophils 
and that the latter engagement counteracts pathogen-induced host immune suppression by 
activating p38 mitogen-activated protein kinase (MAPK) and AKT signaling pathways.  
Siglec-14 is absent from some humans because of a SIGLEC14-null polymorphism, and 
homozygous SIGLEC14-null neutrophils are more susceptible to GBS immune subversion. Finally, 
we report an unexpected human-specific expression of Siglec-5 and Siglec-14 on amniotic 
epithelium, the site of initial contact of invading GBS with the fetus. GBS amnion immune 
activation was likewise influenced by the SIGLEC14-null polymorphism. We provide initial 
evidence that the polymorphism could influence the risk of prematurity among human fetuses  
of mothers colonized with GBS. This first functionally proven example of a paired receptor 
system in the Siglec family has multiple implications for regulation of host immunity.
© 2014 Ali et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
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human gene polymorphism affects the host innate immune 
defense and bacterial pathogenesis is not known. Furthermore, 
it is uncertain whether Siglec-5 and Siglec-14 function inde-
pendently or as paired receptors.
Currently known paired receptors are indeed activating 
and inhibitory membrane receptors with similar ligand bind-
ing domains (Arase and Lanier, 2004; Skokowa et al., 2005). 
Upon activation, they induce signaling pathways in opposite 
directions for a balanced immune response (Arase and Lanier, 
2004). Although the concept of paired receptors was previ-
ously suggested for Siglec-5 and Siglec-14 as well as Siglec-11 
and Siglec-16, it has never been functionally proven in native 
cells (Angata et al., 2006; Crocker et al., 2007; Cao and 
Crocker, 2011; Pillai et al., 2012).
In this work, we study how the presence or absence of 
Siglec-14 influences leukocyte responses to GBS that express 
the Siglec-5–binding -protein. This study is conducted 
through controlled expression of the respective Siglec recep-
tors in cultured macrophages in vitro and by ex vivo analysis 
of blood cells from humans harboring different genotypes 
at the SIGLEC14 locus. Our findings demonstrate that 
Siglec-14 can indeed serve to counterbalance the suppressive 
effects of GBS -protein–mediated engagement of Siglec-5 
on leukocyte activation and reveal roles of mitogen-activated 
protein kinases (MAPKs) and AKT in differential down-
stream signaling. Although Siglecs are appreciated primarily 
as leukocyte receptors, we also uncover a surprising human-
specific expression of Siglec-5 and Siglec-14 on the fetal 
amnion. The human SIGLEC14/5 polymorphism likewise 
influences inflammatory responses of amniotic epithelium 
to GBS, a neonatal pathogen which gains access to the fetus 
through placental membranes. An initial analysis of the 
SIGLEC14/5 polymorphism among premature newborns 
and their mothers suggests that loss of Siglec-14 may influ-
ence the incidence of premature delivery.
RESULTS
Expression of Siglec-14 on THP-1 monocytes  
increases responsiveness to LPS and GBS
It has been suggested but not proven that Siglec-5 and Siglec-14 
are paired receptors that could mediate opposing effects on 
leukocyte responses to bacterial products or bacterial receptor 
engagement. Our prior finding demonstrates that type 1a 
GBS -protein can engage Siglec-5 and deliver an inhibitory 
signal to leukocytes; however, its interaction with Siglec-14 
remained unknown (Carlin et al., 2009a). In keeping with the 
nearly identical ligand-binding domains of the two Siglecs, 
we found that GBS -protein bound equally strongly to 
Siglec-14 Fc-chimera and Siglec-5 Fc-chimera (not depicted). 
To conduct an initial in vitro analysis, we used THP-1 (human 
monocyte like) cells that express only low levels of endog-
enous Siglec-5 and lack Siglec-14 protein (not depicted). 
As described earlier, these cells were stably transfected 
with vectors expressing Siglec-5 (THP-1–Siglec-5), Siglec-14 
(THP-1–Siglec-14), or empty vector control (THP-1–EV; 
 Yamanaka et al., 2009). We observed an increased GBS binding 
endogenous sialoglycans represent the first example of a widely 
distributed “self-associated molecular pattern” (SAMP) that 
can act to dampen leukocyte activation under homeostatic 
conditions (Varki, 2011).
Several important human pathogens including group B 
Streptococcus (GBS), Haemophilus influenzae, Escherichia coli  
K1, Neisseria gonorrhoeae, and Trypanosoma cruzi incorporate si-
alic acids into their terminal glycans, either scavenged directly 
from host or synthesized de novo (Nagamune et al., 2004; 
Crocker et al., 2007; Severi et al., 2007; Carlin et al., 2009b; 
Cao and Crocker, 2011). Such molecular mimicry of host 
sialylated glycans allows the bacterial pathogen to engage in-
hibitory Siglecs, dampen leukocyte activation, and attenu-
ate immune clearance (Carlin et al., 2009b; Diacovich and 
Gorvel, 2010; Hajishengallis and Lambris, 2011; Varki and 
Gagneux, 2012). For example, capsular serotype III GBS 
engages Siglec-9 on human neutrophils to block the oxida-
tive burst, neutrophil extracellular trap (NET) production, 
and bacterial killing, and the sialylated Campylobacter jejuni  
lipooligosaccharide core binds Siglec-7 on dendritic cells to 
modulate T cell polarization (Carlin et al., 2009b; Bax et al., 
2011). In addition to sialic acid–dependent binding, certain 
GBS strains can also engage Siglec-5 through -protein, which 
is anchored to and extends from the bacterial cell wall (Carlin 
et al., 2009a; Nordström et al., 2011). GBS -protein engage-
ment of ITIM-bearing Siglec-5 initiates inhibitory SHP2-
dependent signals that interfere with macrophage activation 
and phagocytic killing (Carlin et al., 2009a).
The fitness costs of pathogen sialic acid mimicry or 
protein-based engagement of inhibitory Siglecs may drive 
evolutionary changes in the host sialic acid repertoire or 
Siglec-binding specificity (Varki, 2009; Varki and Gagneux, 
2012; Wang et al., 2012b; Padler-Karavani et al., 2014). One 
such evolutionary adaptation may be the emergence of acti-
vating Siglecs that hypothetically could function to coun-
teract pathogen immune evasion. In this regard, it is notable 
that all known primate SIGLEC5 genes are undergoing 
partial gene conversions with the adjacent gene SIGLEC14. 
Siglec-14 is thus nearly identical to Siglec-5 in its ligand-
binding domain, but associates with activating DAP12 
adaptor protein bearing ITAM instead of the inhibitory 
ITIM on the cytosolic side (Angata et al., 2006). Interest-
ingly, functional Siglec-14 is missing from certain human 
individuals because of a fusion between the SIGLEC5  
and SIGLEC14 genes leading to a new gene (SIGLEC5*; 
hereafter referred to as SIGLEC14/5), which is identical to 
SIGLEC5 in the coding sequence but is expressed under 
control of the SIGLEC14 promoter (Yamanaka et al., 2009). 
This leads to a polymorphism within the human popula-
tion, where individuals either possess both SIGLEC5 and 
SIGLEC14 or lack one or both alleles of SIGLEC14 as the 
result of its replacement by the SIGLEC14/5 fusion gene.
Recently, we reported that the SIGLEC14 gene poly-
morphism influenced the susceptibility of chronic obstructive 
pulmonary disease (COPD) patients to exacerbations within 
a Japanese cohort (Angata et al., 2013). However, whether this 
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GBS, THP-1 cell variants were infected with GBS at a multi-
plicity of infection (MOI) of 10; GBS infections served 
as negative control for -protein–mediated effects. Interest-
ingly, THP-1 cells expressing Siglec-14 (THP-1–Sig-14) exhib-
ited increased IL-8 protein secretion when infected with WT 
versus mutant GBS (P = 0.06). In contrast, THP-1–Sig-5 cells 
produced less IL-8 protein when infected with WT versus 
mutant GBS (Fig. 1 D). Importantly, IL-8 production was 
significantly enhanced in THP-1–Sig-14 compared with 
THP-1–Sig-5 cells (Fig. 1 D). The enhanced IL-8 protein 
production by THP-1–EV cells infected with WT versus 
mutant GBS was likely caused by endogenous Siglec-5 ex-
pression. Moreover, THP-1–Siglec-5/14 (THP-1 cells over-
expressing Siglec-5 and Siglec-14; Angata et al., 2013) 
produced elevated IL-8 compared with THP-1–Sig-5 but re-
duced IL-8 compared with THP-1–Sig-14 cells, in response 
to THP-1–Siglec-5 and THP-1–Siglec-14 cells compared 
with THP-1–EV control cells (Fig. 1 A). Previous work has 
shown that LPS-triggered cell activation is altered by the sur-
face expression of Siglec-5, -7, -9, -11, and -14 by unknown 
mechanisms (Lock et al., 2004; Wang and Neumann, 2010; 
Pillai et al., 2012). Consistent with prior findings (Yamanaka 
et al., 2009), LPS administration stimulated more TNF mRNA 
production from THP-1–Siglec-14 compared with THP-1–
Siglec-5 and empty vector control (Fig. 1 B). Siglec-14 is 
associated with DAP12 (DNAX activation protein of 12 kD), 
which is known to signal through phosphoinositide-3-kinase 
(PI3K)/Akt pathways (Angata et al., 2006). Enhanced AKT 
activation, as indicated by immunoblot for AKT S473 phos-
phorylation, was observed in THP-1–Siglec-14 compared 
with THP-1–Siglec-5 cells (Fig. 1 C). To investigate the role 
of Siglec-5 and Siglec-14 in the innate immune response to 
Figure 1. Expression of Siglec-14 on 
THP-1 monocytes increases responsiveness 
to LPS and GBS. (A) THP-1 cells expressing 
Siglec-5 (THP-1–Sig-5), Siglec-14 (THP-1–Sig-14), 
or empty vector (THP-1–EV) were infected 
with FITC-labeled GBS or with GBS at 4oC, 
and then bacterial binding to neutrophils at 
the 20-min time point was analyzed by FACS. 
The graph depicts MFI of GFP fluorescence on 
neutrophils. (B) The indicated THP-1 cell vari-
ants were stimulated with 10 ng/ml LPS or 
media control for 2 h, and TNF mRNA was 
measured by Q-RT-PCR and normalized to 
GAPDH mRNA. (C) The indicated THP-1 cell 
variants were stimulated with or without  
10 ng/ml LPS for the indicated times, lysed, 
and analyzed for AKT phosphorylation by 
immunoblot. The p-AKT/actin (×10) densitom-
etry value is shown on the immunoblot.  
(D–F) IL-8 protein was measured in the super-
natant of uninfected THP-1 cell variants and 
those infected with GBS or GBS (MOI = 10) 
for 6 h. (G) The indicated THP-1 cell variants 
were infected or not with GBS, and cell  
lysates were prepared and analyzed for p38 
phosphorylation and IB- degradation by 
immunoblotting. The p-p38/actin and IB-/
actin (×10) densitometry value is shown  
on corresponding blots. All data are repre-
sentative of two to three independent  
experiments. Results are means ± SD;  
*, P < 0.05, **, P < 0.01.
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(Yamanaka et al., 2009), and cells from three to four donors 
with homozygous genotypes were used in this study; separate 
experiments were performed with each donor sample. Pri-
mary monocytes from Sig-14+/+ individuals showed elevated 
TNF production compared with monocytes from Sig-14/ 
individuals after challenge with LPS (Fig. 2 B) or GBS (Fig. 2 C). 
To investigate the role of Siglec-5 and Siglec-14 in primary 
human monocytes, Sig-14+/+ and Sig-14/ cells were in-
fected with GBS at an MOI of 10; GBS infections served 
as negative control for -protein–mediated effects. We observed 
increased p-p38 activation in Sig-14+/+ cells with WT versus 
mutant GBS infection, likely because of activation of Siglec-14 
by WT bacteria. Indeed, as predicted, p-p38 activation was 
reduced in Sig-14/ cells with WT versus mutant GBS in-
fection (Fig. 2 D). Moreover, unlike in THP-1 cells (Fig. 1 F), 
we also observed a moderate increase in NF-B activation, as 
indicated by the disappearance of IB- in GBS-exposed 
Sig-14+/+ compared with Sig-14/ monocytes; GBS  
induced similar NF-B activation in cells of both genotypes 
(Fig. 2 D). Collectively, results from THP-1 cells (Fig. 1) 
and from monocytes from healthy human donors without 
or with SIGLEC14/5 polymorphism (Fig. 2) indicate that 
Siglec-14 promotes proinflammatory responses to LPS and 
GBS through activation of AKT and/or p38 MAPK path-
ways, thus providing an opposing force to Siglec-5, which acts 
via a cytosolic ITIM motif that recruits the tyrosine phospha-
tases SHP-1 and SHP-2 (Carlin et al., 2009a).
to GBS but not GBS (Fig. 1, E and F). Thus, our results 
demonstrate an activatory role of Siglec-14 in GBS -protein–
mediated responses.
Infection with GBS also led to enhanced p38 MAPK 
phosphorylation in THP-1–Siglec-14 compared with THP-1– 
Siglec-5 cells (Fig. 1 G). In contrast, similar amounts of 
NF-B activation were observed across the THP-1 cell vari-
ants after GBS challenge, as indicated by similar disappearance 
of the IB- protein (Fig. 1 G). Together, our results demon-
strate that expression of Siglec-14 on THP-1 cells increases 
responsiveness to LPS and GBS.
SIGLEC14/5 gene polymorphism influences  
primary human monocyte responses to LPS and GBS
Based on the in vitro THP-1 experiments, we hypothesized 
that the human-specific SIGLEC14/5 gene polymorphism 
could influence the responsiveness of primary human mono-
cytes to infectious agents. The 5 regions of SIGLEC5 and 
SIGLEC14 exhibit high similarity as the result of ongoing 
gene conversion, and in some individuals, the two are fused 
into a single gene that encodes for a functionally Siglec-5 gene 
product expressed under the SIGLEC14 promoter (Fig. 2 A; 
Yamanaka et al., 2009). The homozygous state of this allele 
is hereafter referred to as Sig-14/, whereas the homozy-
gous state of the ancestral WT alleles carrying Siglec-5 and 
Siglec-14 is denoted as Sig-14+/+. Genotype analysis of 
blood cells was performed and analyzed as described previously 
Figure 2. The Siglec-5/14 genotype influences primary human monocyte responses to LPS and GBS. (A) Pictorial representation of SIGLEC-14/5 
polymorphism in humans. Highly similar regions of SIGLEC14 and SIGLEC5 resulted in the generation of a SIGLEC14/5 fusion gene, leading to deletion of 
SIGLEC14 and expression of SIGLEC5 under the SIGLEC14 promoter. (B) Human blood monocytes of the indicated genotypes were left unstimulated (Ctrl) or 
stimulated with 10 ng/ml LPS, and TNF protein release was measured at 6 h by ELISA. (C) Human blood monocytes of the indicated genotypes were left un-
infected (Ctrl) or infected with GBS at MOI = 10, and TNF protein release was measured at 6 h by ELISA. (D) Human monocytes of the indicated genotypes 
were left uninfected or infected with GBS or GBS for the indicated times and then lysed and analyzed for phosphorylation of p38 MAPK and IB- deg-
radation by immunoblot. The p-p38/actin and IB-/actin (×10) densitometry values are shown on corresponding blots. Data in B–D are representative of 
two to four independent experiments with one to three different donors per genotype in each experiment. Results are means ± SD; *, P < 0.05.
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thus indeed act as a paired receptor system (Crocker et al., 
2007; Pillai et al., 2012). Balanced activities of other paired 
activating and inhibitory receptors are critical for effective 
immune responses (Kumar et al., 2006; Barclay and Hatherley, 
2008). One mechanism underlying such a balance is the co-
ordinated regulation of receptor expression; for example, the 
inhibitory receptor is down-regulated at the same time that 
the activating receptor is up-regulated (Skokowa et al., 2005; 
Kumar et al., 2006). Primary human neutrophils of the indi-
cated genotypes were treated with LPS for 2 h, and receptor 
mRNA was quantified by Q-RT-PCR. In Sig-14+/+ neu-
trophils, SIGLEC5 mRNA was down-regulated, whereas 
SIGLEC14 mRNA was up-regulated in response to LPS 
(Fig. 3, E and F). Similar results were obtained when neutro-
phils were stimulated with a TLR2 ligand, PamCys3K (not 
depicted). Interestingly, SIGLEC5 expression was increased 
in Sig-14/ neutrophils (Fig. 3 E), likely because of pro-
moter swapping that leads to expression of Siglec-5 under the 
Siglec-14 promoter (Fig. 2 A).
TLR priming increases GBS suppression of Sig-14/  
but not Sig-14+/+ neutrophil responses
Because TLR-4 activation by LPS reduced the expression of 
Siglec-5 in Sig-14+/+ neutrophils but increased expression in 
SIGLEC14/5 gene polymorphism influences  
human neutrophil responses to GBS
Neutrophils are the critical first line phagocytic cells in innate 
immune defense against invasive bacterial pathogens. Sig-14+/+ 
human neutrophils killed GBS more efficiently than those iso-
lated from Sig-14/ individuals (Fig. 3 A). The difference in 
killing of GBS and GBS in Sig-14+/+ neutrophils was not 
statistically significant, probably because of the offsetting effect of 
endogenous Siglec-5. To confirm that the reduced GBS killing 
by Sig-14/ neutrophils reflects the absence of Siglec-14 by it-
self, the Siglec-14 activity of Sig-14+/+ neutrophils was disrupted 
using an antibody that specifically recognizes Siglec-14 but 
not Siglec-5 (Yamanaka et al., 2009). Anti–Siglec-14 anti-
body–treated neutrophils killed GBS less efficiently than neutro-
phils treated with an isotype control antibody in a dose-dependent 
manner (Fig. 3 B). These differences in cytokine release and 
killing do not reflect differential overall binding of GBS to the 
neutrophil surface, which was similar in Sig-14+/+ and Sig-14/ 
neutrophils and dependent on -protein expression (Fig. 3 C). 
Upon LPS challenge, neutrophils from human donors with the 
Sig-14+/+ genotype also produced significantly higher levels of 
IL-8 transcript than Sig-14/ neutrophils (Fig. 3 D).
Given the nearly identical ligand-binding domains and 
opposing intracellular functions, Siglec-5 and Siglec-14 may 
Figure 3. The Siglec-5/14 genotype influences  
human neutrophil responses to GBS. (A) Human neutro-
phils of the indicated genotypes were left uninfected or 
infected with GBS or GBS (MOI = 5), and bacterial  
survival at 40 min was assessed by CFU enumeration.  
(B) Sig-14+/+ neutrophils were pretreated with the indicated 
concentrations of anti–Siglec-14 antibody (Ab) for 15 min, 
followed by GBS infection as in A; after 40 min, bacterial 
survival was assayed by CFU enumeration. Data are repre-
sentative of three independent experiments with one donor 
in each experiment. (C) Human neutrophils of the indicated 
genotypes were infected with FITC-labeled GBS or with 
GBS at 4°C, and then bacterial binding to neutrophils at 
the 20-min time point was analyzed by FACS. The graph 
depicts MFI of GFP fluorescence on neutrophils. (D–F) Human 
neutrophils of the indicated genotypes were left unstimu-
lated or stimulated with LPS, and IL-8 (D), Siglec-5 (E), 
and Siglec-14 (F) mRNA were analyzed by Q-RT-PCR at 2 h. 
Results were normalized to the amount of GAPDH mRNA. 
Data in this figure are representative of two to four inde-
pendent experiments with one to three different donors  
per genotype in each experiment. Results are means ± SD;  
*, P < 0.05, **, P < 0.01.
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Figure 4. TLR priming increases GBS suppression of Sig-14/ but not Sig-14+/+ neutrophil responses. (A) Human neutrophils of the indicated 
genotypes were left unstimulated or stimulated with LPS for 6 h, incubated with H2DFCA for 30 min, and then infected with GBS (MOI = 10); ROS  
production was measured 20 min after infection by FACS. The histogram shows fluorescence of ROS indicator H2DCFDA. (B) Human neutrophils of the 
indicated genotypes were left unstimulated or stimulated with LPS for 6 h and infected with GBS (MOI = 10), and NET formation was visualized by myelo-
peroxidase and DAPI staining 30 min after infection. Bar, 50 µm. (C) Quantification of NETs shown in B. (D) Human neutrophils of the indicated genotypes 
were left unstimulated or stimulated with LPS for 8 h; expression of Siglec-5 and Siglec-14 was analyzed by FACS using antibody recognizing both human 
Siglec-5 and Siglec-14. The histogram depicts combined surface expression of Siglec-5 and Siglec-14. (E) Human neutrophils of the indicated geno-
types were stimulated or not with LPS for 6 h and infected with GBS (MOI = 10), and bacterial killing was assayed 20 min after infection. (F) Human  
neutrophils of the indicated genotypes were stimulated with LPS for 6 h and infected with GBS (MOI = 10), and cell lysates prepared at the indicated 
times were immunoprecipitated with Siglec-5– and Siglec-14–recognizing antibody. SHP-1 recruitment and total IgG were analyzed by immunoblot. The 
SHP-1/IgG (×10) densitometry value is shown on the immunoblot. Data in this figure are representative of two to four independent experiments with one 
to three different donors per genotype in each experiment. Results are means ± SD; *, P < 0.05, **, P < 0.01.
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of the placental membranes, gaining access to the amniotic 
fluid and fetus and leading to the potentially life-threatening 
early-onset pneumonia and sepsis (Edwards et al., 2011). The 
ability of fluorescently labeled GBS to bind to AM was estab-
lished, and the key contribution of the surface-anchored 
Siglec-binding -protein was confirmed (Fig. 5 B).
We next addressed the effects of the SIGLEC14/5 poly-
morphism on AM responses to GBS. -Protein–mediated 
binding to Sig-14/ AM was accompanied by reduced IL-6 
mRNA induction (Fig. 5 C). Elevated IL-6 is produced in 
response to cytokine stimulation and bacterial infections 
(Keelan et al., 1997). To determine how GBS modulates AM 
inflammatory responses, Sig-14/ AMs were infected with 
GBS or GBS, lysates were prepared at the indicated times, 
and immunoblotting was performed for activation of signal-
ing molecules. GBS, but not WT GBS, induced activation 
of p38 MAPK, AKT, and S6-mTOR pathways, as indicated 
by respective protein phosphorylation, indicating an impor-
tant role of the -protein in suppressing AM inflammatory 
responses (Fig. 5, D and E). However NF-B activation in re-
sponse to GBS, as assessed by the disappearance of IB-, was 
not affected by -protein (Fig. 5 D).
To uncover a potential role of the SIGLEC14/5 poly-
morphism in modulating GBS -protein–mediated suppression 
of AM inflammatory responses, freshly collected Sig-14+/+ 
and Sig-14/ AMs were stimulated with either GBS or 
GBS, and at indicated times, the cell lysates were made 
and probed for AKT phosphorylation. To avoid any differences 
that may arise as the result of AM handling procedure in 
labor rooms, GBS and GBS infection–induced responses 
were always compared using the same AM. AKT inhibition by 
GBS relative to GBS was diminished in Sig-14+/+ amnion 
when compared with Sig-14/ amnion (Fig. 5 F). Our re-
sults suggest that Siglec-14 activation prevents the -protein–
mediated, Siglec-5–dependent immune suppression of AMs. 
The opposing functions of Siglec-5 and Siglec-14 represented 
in Fig. 5 F provide further support for a functional Siglec-5 
and Siglec-14 paired receptor system.
Amniotic expression of Siglec-14 may influence the incidence 
of preterm birth in the context of GBS infections
Our findings reveal an important role of Siglec-14 in control-
ling the inflammatory response of AMs to GBS challenge. 
Because GBS ascending infection can precipitate premature 
delivery, we performed an initial genotype–phenotype corre-
lation to probe whether the presence or absence of Siglec-14 
can affect the gestation period of human infants, especially if 
the pregnancy was associated with a positive maternal screen 
for GBS rectovaginal colonization. A cohort of samples (n = 
1,228; collected from Iowa [University of Iowa Hospitals and 
Clinics], Rochester, Pittsburgh, and Wake Forest) was divided 
into three groups based on available clinical information: 
(1) infants of GBS-positive pregnancies, (2) infants of GBS-
negative pregnancies, and (3) mothers of GBS-positive preg-
nancies (Fig. S1 A). The three groups were analyzed for a 
correlation between the presence or absence of Siglec-14 and 
Sig-14/ neutrophils (Fig. 3 E), we hypothesized that preac-
tivation of TLR-4 signaling in Sig-14/ neutrophils would 
significantly increase their susceptibility to GBS-mediated 
immune suppression. Two phenotypes that are suppressed upon 
GBS Siglec-5 engagement are reactive oxygen species (ROS) 
generation and formation of DNA-based NET (Carlin et al., 
2009a). To test our hypothesis, neutrophils of the indicated 
genotypes were pretreated with LPS or media control for 8 h, 
followed by low-dose GBS infection for 30 min. No signi-
ficant increase in ROS or NET formation was observed in 
response to GBS stimulation alone after 30 min. However, 
LPS priming induced significant ROS and NET production 
in GBS-infected Sig-14+/+ but not Sig-14/ neutrophils 
(Fig. 4, A–C). Surface expression of Siglec-5 and Siglec-14 
was determined by flow cytometry using an antibody that 
recognizes both Siglec-5 and Siglec-14 (currently no specific 
antibody exists that is specific for Siglec-5 only). As indicated 
in Fig. 4 D, an LPS-mediated increase in mean fluorescence 
intensity (MFI) from 32 (control) to 78 (LPS) in Sig-14+/+ 
corresponds to Siglec-5/14 expression, whereas the observed 
increase from 30 to 135 in Sig-14/ neutrophils corresponds 
to Siglec-5 expression alone. The increase of Siglec-5 expres-
sion in Sig-14/ neutrophils may contribute, along with the 
absence of the activating Siglec-14 receptor, to the enhanced 
susceptibility of Sig-14/ neutrophils to immune suppres-
sion by GBS. Consistent with this model, neutrophil killing 
of GBS was significantly reduced in LPS-treated Sig-14/ 
compared with Sig-14+/+ neutrophils (Fig. 4 E). In contrast, 
GBS survival was similar between the two genotypes (not 
depicted). To analyze the molecular events associated with 
Siglec receptor activation in LPS + GBS–treated neutrophils, 
cells were LPS pretreated or not for 8 h, followed by GBS 
infection for 20 min. When neutrophil lysates were immuno-
precipitated by antibody recognizing human Siglec-5 and 
Siglec-14, followed by immunoblotting for SHP-1, we found 
that LPS priming + GBS infection increased recruitment of 
inhibitory SHP-1 in Sig-14/ compared with Sig-14+/+ 
neutrophils (Fig. 4 F), consistent with the initiation of inhibi-
tory signaling through Siglec-5 (Carlin et al., 2009a).
Unexpected expression of Siglec-5 and Siglec-14 on human 
amniotic membranes influences inflammatory responses to GBS
CD33-related Siglecs are mainly present on immune cells 
(Crocker et al., 2007). One exception is Siglec-6, which was 
unexpectedly found on the placental trophoblast (Brinkman- 
Van der Linden et al., 2007). While screening for other Siglecs 
in fetal tissues, we were surprised to find positive staining on 
the amniotic epithelial membrane (AM) of human placental 
sections with the antibody that recognizes Siglec-5 and 
Siglec-14 (Fig. 5 A). This staining is apparently unique to 
the human amnion, as it was not found in amnions from the 
closely related great apes (not depicted). Siglec-5 and Siglec-14 
protein expression on human AM was confirmed by Western 
blot (not depicted). This unusual tissue site of Siglec human-
specific expression is particularly intriguing because the 
human-specific pathogen GBS produces ascending infections 
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Figure 5. The unusual ectopic expression of Siglec-5 and Siglec-14 on human AMs influences inflammatory responses to GBS. (A) Human 
AMs were stained for Siglec-5 and Siglec-14 expression using a human Siglec-5– and Siglec-14–recognizing antibody and Siglec-14 antibody by im-
munohistochemistry. (B) Human AMs were incubated either with FITC-labeled GBS or FITC-labeled GBS, and bacterial binding to the membrane 
was analyzed by fluorescence microscopy. (A and B) Bars, 50 µm. (C) Sig-14/ AMs were cut into small pieces of similar size and infected either with 
GBS or GBS; IL-6 mRNA was analyzed by Q-RT-PCR after 2 h of infection. Results were normalized to GAPDH mRNA. Results are means ± SD;  
*, P < 0.05. (D and E) Sig-14/ AMs were infected either with GBS or GBS as above. At the indicated times, cell lysates were prepared and ana-
lyzed for p38 phosphorylation and IB- degradation (D) and phosphorylation of AKT and S6 (E) by immunoblotting. (F) AMs of the indicated geno-
types were infected either with GBS or GBS. At the indicated times, cell lysates were prepared and analyzed for phosphorylation of AKT protein by 
immunoblotting. The p-AKT/tubulin (×10) densitometry ratio is shown on the blot. p-AKT/tubulin, IB-/tubulin, and p-S6/tubulin (×10) densitometry 
values are shown on corresponding blots. Data in A–F are representative of two to five independent experiments with two to three different amnions 
per genotype in each experiment. (G–L) Human amnion genotyping: Association of the SIGLEC14-null allele with preterm birth in infants of GBS-
positive pregnancies. (G and H) Tables showing distribution of WT and null alleles in term and preterm groups in infants of GBS+ (G) and GBS (H) 
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(SIGLEC14 with SIGLEC5 and SIGLEC16 with SIGLEC11; 
Angata et al., 2006; Crocker et al., 2007; Cao and Crocker, 
2011; Wang et al., 2012a). In both instances the gene conver-
sion events only involved the genomic segments encoding 
the first two domains of the proteins, thus homogenizing the 
ligand properties while maintaining the potential for oppos-
ing signaling functions. Based on such findings, it has been 
suggested (but not proven) that the 11/16 and 5/14 pairs have 
evolved to provide an appropriately balanced response to 
pathogens that seek to subvert the inhibitory versions. Here 
we address this hypothesis for the first time, also taking advan-
tage of the natural human polymorphism in the Siglec-5/14 
pair. In keeping with the hypothesis, our findings demonstrate 
that Siglec-14 counterbalances the inhibitory effects of GBS 
engagement to Siglec-5 on human monocytes and neutrophils. 
In response to LPS or GBS challenge, Siglec-14 promotes in-
creased innate immune and inflammatory responses by acti-
vating p38 MAPK and AKT signaling pathways (while not 
affecting NF-B activation).
This study also presents an unexpected finding of uniquely 
human Siglec-5 and Siglec-14 expression on the fetal-derived 
placental amnion, a tissue which would encounter GBS in the 
course of ascending infection of the womb during pregnancy 
(Doran and Nizet, 2004; Edwards et al., 2011). The inflam-
matory responses provoked by GBS in ex vivo challenge of 
AMs were likewise influenced by the presence or absence of 
Siglec-14. An initial genotype–phenotype correlation analysis 
of GBS status and gestation length of human pregnancies sug-
gests that fetuses with the SIGLEC14/5 polymorphism that 
results in Siglec-14 protein deficiency may be more likely to 
be born preterm if infected with GBS. The Siglec-5– and 
Siglec-14–dependent manifestations highlight the potential 
role of sialic acid in amnion–fetus biology and innate immune 
defense. A unique feature of our study was that most of the ex-
periments were performed either on fresh human peripheral 
blood cells or amnions obtained from randomly selected donors 
after Siglec genotyping. Results from fresh blood cells were 
corroborated in a panel of cultured THP-1 cells overexpress-
ing Siglec-5 or Siglec-14 to exclude outbreeding effects.
ITIM-bearing receptors such as SIRP-, PIR-B, and 
Ly49-I are attractive targets for pathogen engagement to 
attenuate host immune responses (Arase and Lanier, 2004; 
Diacovich and Gorvel, 2010; Akkaya and Barclay, 2013). 
However, evolution of activating counterpart receptors like 
SIRP-, PIR-A1, and Ly49-H suggests a host strategy to 
counterbalance pathogen manipulation (Abi-Rached and 
Parham, 2005; Diacovich and Gorvel, 2010; Akkaya and Barclay, 
2013). Our study is the first to demonstrate in functional 
terms the existence of a paired receptor system in the Siglec 
gestation period, defining preterm birth as delivery before 
36 wk and term birth as 36 wk or later. Fig. 5 (G–L) and 
Fig. S1 show different analyses on the same cohort of samples. 
The genotype distribution data are shown in Fig. S1 (B–D).
Interestingly, our results showed that in GBS-positive 
pregnancies, preterm birth tended to be often associated with 
a SIGLEC14-null allele in infants (Fisher’s exact test; infant 
allele × term/preterm; P = 0.11; Fig. 5 G). A similar correla-
tion was not observed in the infant group with GBS-negative 
pregnancies (Fisher’s exact test P = 0.93; Fig. 5 H). Although 
the preterm percentage in the current cohort is higher than the 
normal occurrence (15% of total birth), the lack of associa-
tion between the SIGLEC14-null allele and preterm birth in 
infants of GBS-negative pregnancies served as the internal 
negative control (Fig. 5, G–L).
In a subsequent analysis on the same cohort of samples, we 
examined the percentage of each genotype in term and pre-
term in the GBS-positive infant group. Similar to the previous 
result (Fig. 5 G), a higher percentage of preterm babies was ob-
served in Sig-14/ infants compared with Sig-14+/+ infants 
(83 vs. 66%; Fig. 5 K). Similar correlations were not observed in 
the infant group with GBS-negative pregnancies or mothers of 
GBS-positive pregnancies (Fig. 5 J and Fig. S1 E).
We next evaluated the risk of GBS colonization in the pre-
term group from the same cohort, comparing Siglec genotypes. 
Our result demonstrates that in preterm babies (n = 631), GBS 
colonization has a statistically significant association with the 
SIGLEC14-null allele compared with the WT allele (Fisher’s 
exact test; infant allele × GBS pos/neg infants; P = 0.03; Fig. 5 L). 
Together, our analysis of the cohort of human amnion samples 
indicates a regulatory role of Siglec-5 and Siglec-14 in GBS- 
associated amnion infections and preterm birth of human babies. 
Although the number of Sig-14/ samples studied is lower 
than Sig-14+/+ samples in all the groups (Fig. S1, B–D), no as-
sociation between the SIGLEC14-null allele and preterm birth 
in infants of GBS-negative pregnancies or mothers of GBS-
positive pregnancies was observed, serving as an internal nega-
tive control (Fig. 5, G–L).
DISCUSSION
Since the discovery of potentially activating CD33-related 
Siglecs in primates (Siglec-13, -14, -16, and 17), the question 
has arisen as to what their function might be. Siglec-13 and 
Siglec-17 were eliminated in the human lineage before the 
common origin of humans in Africa and possibly represent an 
infection-related signature of the proposed population bottle-
neck at that origin (Wang et al., 2012b). The two activating 
CD33rSiglecs that have persisted intact in humans have both 
undergone partial gene conversions with inhibitory counterparts 
pregnancies. Fisher’s exact test was performed using data computing infant allele × term/preterm. (I and J) Percentage of infants with various geno-
types (Sig-14+/+, Sig-14+/, or Sig-14/) in preterm and term group; infants from GBS-positive and -negative pregnancies were analyzed in I and J, 
respectively. (K) Table showing the ratio of preterm to term genotype percentage obtained from I and J. (L) Association of SIGLEC14/5 alleles with GBS 
colonization in preterm infants. The table shows the distribution of WT and null alleles in GBS-positive and -negative infants in the preterm group 
only. Fisher’s exact test was performed using data computing infant allele × term/preterm.
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background (Doran and Nizet, 2004; Ananth and Vintzileos, 
2008; Anum et al., 2009; Dolan, 2010; Tikkanen, 2011). Poly-
morphisms in various pro- and antiinflammatory cytokine 
genes are linked to differential susceptibility to prematurity 
(Anum et al., 2009). These factors may predispose to infection 
and/or provoke inflammation, events which are implicated 
in precipitating early labor (Anum et al., 2009). GBS is one of 
the leading pathogens in infection associated with preterm 
deliveries (Doran and Nizet, 2004), and our initial geno-
type–phenotype study suggests that the SIGLEC14/5 gene 
polymorphism may be overrepresented in a preterm cohort 
among GBS-positive pregnancies. Fetuses with this polymor-
phism lack Siglec-14 and would be more susceptible to GBS-
induced blunting of innate immune responses in leukocytes 
and AM. Additional functional and epidemiological studies 
will be needed to address this issue further.
Evolution of paired receptors may be driven by pathogens 
(Abi-Rached and Parham, 2005; Akkaya and Barclay, 2013) 
but counterbalanced by risks of inflammatory disease. The 
SIGLEC14/5 polymorphism predisposes to GBS susceptibil-
ity but also reduces the risk of inflammatory COPD exacer-
bations in a Japanese cohort (Angata et al., 2013). Our research 
revitalizes the notion that coexistence of host and pathogens 
in association with the dynamic environment may promote 
evolutionary changes in the host in multiple directions.
MATERIALS AND METHODS
Bacterial strains and reagents. GBS type Ia strain A909 expressing the 
-protein and its isogenic -protein–negative mutant GBS have been 
described previously (Carlin et al., 2009a; Nordström et al., 2011). Fluorescent-
labeled and unlabeled anti–Siglec-5 antibodies were obtained from R&D Sys-
tems (clones 194128 and 194117, respectively). Anti–Siglec-14 antibody has 
been characterized previously (Yamanaka et al., 2009). Immunoblot analysis 
was performed with antibodies recognizing phospho-p38 and phospho-AKT 
(Cell Signaling Technology) and IB- (Sigma-Aldrich).
Ethics approvals. Permission to obtain human blood and amnions was re-
ceived from the Institutional Biosafety Committee of University of Califor-
nia, San Diego. Human volunteers provided informed consent before blood 
samples were obtained.
THP-1 cell activation with live GBS and LPS. The human monocytic 
cell line THP-1 overexpressing Siglec-5 or Siglec-14 (Yamanaka et al., 2009) 
was infected with various GBS variants or activated by 10 ng/ml LPS (055:
B5; Sigma-Aldrich) as indicated in the figure legends. Cytokine, transcript, 
and protein production analysis was performed as described below.
Human neutrophil, monocyte, and amnion isolation. Neutrophils from 
three to six different donors per genotype were used in this study. Neutrophils 
were isolated from whole blood using Polymorphprep solution as previously de-
scribed (Carlin et al., 2009a). Monocytes were purified from the mononu-
clear cell fraction of Polymorphprep by passing them through a magnetic CD14 
MACS cell separation kit (Miltenyi Biotech). Freshly isolated sterile human pla-
centas obtained from caesarian section were used for preparation of AM. AMs 
were carefully separated from chorion using sterile tweezers, washed with PBS 
three times to remove any attached red blood cells, and cut into small pieces of 
almost equal size (1-cm square) for use in various assays. Neutrophils and AMs 
were genotyped as previously described (Yamanaka et al., 2009).
Human neutrophil, monocyte, and amnion infection with GBS. 
GBS was propagated in Todd-Hewitt broth (Oxoid) at 37°C without shaking 
family, where Siglec-5 and Siglec-14 invoke differing responses 
in peripheral blood cells as well as placental membranes upon 
GBS encounter. Absence of the activating paired receptor 
provides an advantage to the pathogen, resulting in enhanced 
host susceptibility to infection (Rhein et al., 2008). Accord-
ingly, we found that Siglec-14 deficiency on neutrophils ben-
efits microbial survival. Although an experimentally induced 
Siglec-5 deficiency in primary cells could not be achieved in 
our hands through shRNA technology, we had the opportu-
nity to analyze Siglec-14–deficient cells from natural popula-
tions. We previously demonstrated GBS -protein–dependent 
suppression of immune responses in Sig-14/ neutrophils 
(Nordström et al., 2011). Here we found that Sig-14/ AM 
(possessing only Siglec-5) shows less activation of immune 
signaling pathways upon GBS infection when compared with 
Sig-14+/+ AM. Together, these findings establish that the Siglec 
paired receptor system plays an important role in modulating 
GBS pathogenesis.
Balanced activity of paired receptors is critical for effective 
immunity (Skokowa et al., 2005). One mechanism sustaining 
this balance is modulation of receptor expression, wherein the 
inhibitory receptors are down-regulated or modified, at which 
time the activating sibling may continue to operate and pro-
mote an inflammatory response (Skokowa et al., 2005; Kumar 
et al., 2006). The present study provides evidence that Siglec-5 
and Siglec-14 mRNA expression levels are modulated in in-
verse directions upon LPS challenge. Although corresponding 
changes in receptor levels on the host cell surface cannot cur-
rently be quantified because of a lack of specific antibodies dis-
criminating between Siglec-5 and Siglec-14, our findings do 
indicate that LPS-primed neutrophils, depending on Siglec-14 
status, exhibit different patterns of Siglec-5 expression. We 
could not find in prior literature any other example of a mole-
cule possessing this unique characteristic in which a pro-
moter change (SIGLEC5 under SIGLEC14 promoter in 
SIGLEC14/5 fusion) is linked to differential expression. Changes 
in Siglec-5 expression may contribute to differences in immune 
responses between Sig14+/+ and Sig-14/ neutrophils during 
subsequent GBS challenge.
LPS-triggered cell activation is also influenced by the sur-
face expression of Siglec-5, -7, -9, -11, and -14 (Lock et al., 
2004; Wang and Neumann, 2010; Pillai et al., 2012). There is 
no current evidence of direct activation of Siglecs by LPS, and 
therefore the mechanism for this association remains to be 
fully elucidated. Nevertheless, these findings help corroborate 
a key role for Siglec interaction with host sialic acid (e.g., in-
teractions in -cis) in regulating the tonic activation state of 
leukocytes. One likely contributing factor is the ability of the 
Siglec-associated SHIP/DAP12 adaptor molecules to modu-
late downstream signaling (Wielgat et al., 2012). However, it 
could also be interesting to explore in future studies an addi-
tional unifying mechanism wherein Siglecs may alter the sur-
face configuration or coaggregation of sialylated TLRs (Wielgat 
et al., 2012).
There are multiple potential risk factors for preterm birth, 
including socioeconomic status, environment, and genetic 
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images per sample. For ROS assay, cells were incubated with H2DCFDA 
fluorescent dye (Invitrogen) along with GBS infection; ROS production 
was analyzed by flow cytometry.
Statistical analysis. In ex vivo experiments, the differences in mean values 
between groups were analyzed using a two-tailed unpaired Student’s t test: 
*, P < 0.05; **, P < 0.01. Statistical analyses on amnion samples were per-
formed on GraphPad QuickCalcs and GraphPad Software using the two-
tailed Fisher’s exact test.
Online supplemental material. Fig. S1 shows the human amnion geno-
type–phenotype study. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20131853/DC1.
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